Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465164 | 0.77 | AAK1 (0.32) | AAK1 | |
| SCHEMBL3466321 | 0.70 | MEN1 (0.34) | ALDH1A1AAK1CPB2 | |
| SCHEMBL8570722 | 0.69 | ALDH1A1 (0.51) | ALDH1A1LMNA | |
| SCHEMBL3465845 | 0.69 | CYP1A2 (0.49) | ALDH1A1LMNA | |
| SCHEMBL13215105 | 0.68 | HDAC6 (0.36) | AAK1 | |
| SCHEMBL6024012 | 0.67 | LMNA (0.49) | ALDH1A1LMNA | |
| SCHEMBL1859771 | 0.66 | CA14 (0.40) | — | |
| SCHEMBL18619385 | 0.66 | CA14 (0.40) | — | |
| SCHEMBL8328107 | 0.65 | HDAC6 (0.36) | AAK1 | |
| SCHEMBL7959585 | 0.65 | TDP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | ALDH1A1 1875/4885LMNA 4322/4885AAK1 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.